Review Article
DOI: https://doi.org/10.70749/ijbr.v3i8.2150

INDUS JOURNAL OF BIOSCIENCE RESEARCH
https://ijbr.com.pk
ISSN: 2960-2793/ 2960-2807

Pharmaceutical Manufacturing's Horizon Challenges and Opportunities in Continuous Processing, Advanced Therapy Medicinal Products Regulatory Adaptation, and Quality by Design / Process Analytical Technology Integration

Mehwish Nisar[1], Huma Dilshad[2], Khurram Rafiq Ahmed[3], Saria Tariq[4], Sidra Siddiqui[5]

[1]Department of Pharmaceutics, Faculty of Pharmacy, Hamdard University, Karachi, Pakistan.
[2]Department of Pharmaceutics, Faculty of Pharmacy, Jinnah University for Women, Karachi, Pakistan.
[3]Director, BF Biosciences.
[4]Department of Pharmaceutics, Faculty of Pharmacy, Hamdard University, Karachi, Pakistan.
[5]Department of Pharmaceutics, Faculty of Pharmacy, Hamdard University, Karachi, Pakistan.

ARTICLE INFO

Keywords: Continuous Manufacturing, Quality by Design (QbD), Process Analytical Technology (PAT), Advanced Therapy Medicinal Products (ATMPs), Real-time Release Testing (RTRT).

Correspondence to: Mehwish Nisar, Lecturer, Department of Pharmaceutics, Faculty of Pharmacy, Hamdard University, Karachi, Pakistan.
Email: mehwish.nisar@hamdard.edu.pk

Declaration
Authors' Contribution: All authors equally contributed to the study and approved the final manuscript.

Conflict of Interest: No conflict of interest.

Funding: No funding received by the authors.

Article History
Received: 28-06-2025 Revised: 13-08-2025
Accepted: 20-08-2025 Published: 30-08-2025

ABSTRACT

Background: The pharmaceutical industry is evolving, focusing on the quality, efficacy, and accessibility of innovative treatments while incorporating QbD, PAT, and regulatory frameworks, despite challenges like high initial investment and system complexity. **Objective:** This review looks at pharmaceutical manufacturing, paying special attention to quality by design, continuous manufacturing, regulatory concerns, challenges with advanced therapy medications, and the use of process analytical technology. **Methodology:** This review looks at the technological challenges, financial implications, regulatory changes, benefits, drawbacks, digital transformation, and interdisciplinary collaboration of continuous manufacturing, ATMPs, QbD, and PAT. **Conclusion:** The pharmaceutical manufacturing sector is going through a significant transition as continuous manufacturing offers efficient, high-quality drug manufacture. It is crucial to successfully integrate CM, regulatory adaptation, QbD and PAT, interdisciplinary collaboration, trained staff, and digital solutions in order to create safer, more effective, and more accessible medications.

INTRODUCTION

Pharmaceutical Continuous Manufacturing: Advantages, Difficulties, and Regulatory Environment

The pharmaceutical industry is changing as a result of Continuous Manufacturing's (CM) shift from traditional batch processes to integrated flow. It solves technical and legal problems while providing effectiveness, quality, and flexibility.[1]

Enhanced Productivity & Lower Expenses: Continuous operations increase efficiency and reduce costs because they involve faster production cycles, require less labor, and produce less waste.[2] As a result, costs are reduced overall and expenses and time to market are shortened.[1, 3, 4]

Enhanced Product Quality: Continuous production improves product quality by using Process Analytical Technology (PAT) for real-time monitoring and control.[5] This proactive approach reduces the risk of batch failure and the requirement for post-production testing.[6, 7]

Flexibility & Agility: A smaller, modular design that minimizes the production footprint and facilitates easy scaling up or down operations is made possible by the agility and flexibility that continuous manufacturing offers.[8] It also makes it possible to react quickly to market demands.[7, 9]

Supply Chain Resilience: Continuous manufacturing increases supply chain resilience and reduces reliance on distant supply chains by reducing the likelihood of a medication shortage and promoting local manufacturing initiatives.[4, 10]

Copyright © 2025. IJBR Published by Indus Publishers
This work is licensed under a Creative Commons Attribution 4.0 International License.

Challenges and Limitations

Technical Complexity: To integrate and control continuous operations, especially for complex formulations, advanced tools and knowledge are required.[11, 12]

Material Properties: Because raw material variability can impact process stability, excipient properties must be carefully regulated.[12]

Implementation Costs: The significant upfront costs of new technology and training are outweighed by the long-term advantages.[2, 3]

Environmental Impact: Some procedures may use more solvents or cause new waste issues, even though the majority are more environmentally friendly.[13, 14]

Benefits of Continuous Manufacturing: Continuous manufacturing (CM) increases efficiency and reduces costs by streamlining production, minimizing waste, using less energy and raw materials, and enabling smaller, more flexible facilities.[15]

Increased Throughput

A hybrid process in bio manufacturing demonstrates how CM boosts throughput and responsiveness to demand fluctuations, resulting in increased mass per cycle and productivity.[1, 9, 15, 16]

Decreased Lead Times:

By utilizing CM and process management technologies, monthly production capacity can be increased by over 40% and lead times, like those in semiconductor manufacturing, can be shortened by five working days.[1]

Real-Time Quality Control: Continuous monitoring and automated procedures reduce human error, ensure consistent product quality, and allow for quick corrective action.[17]

Lower Operating and Capital Costs: CM reduces labor, material, and facility costs. CM allows for the construction of smaller, less costly facilities while lowering waste, energy, and raw material consumption in the pharmaceutical sector.[2]

Savings on Catalysts and Raw Materials: As catalyst activity maintenance improves, CM can reduce manufacturing costs in chemical manufacturing by 37–75% when compared to batch operations.[18]

Labor and Direct Costs: CM can reduce labor costs and direct processing/material costs by up to 20% through better process balance and automation.[15]

Table 1

Key Advantages of Continuous Manufacturing in a Summary Table

Benefit	Example/Impact	References
Increased productivity	45-fold increase in biomanufacturing output	(9, 15)
Reduced lead time	5 days shorter in semiconductor production	(15)
Lower labor/material costs	20% labor cost reduction; 75% less process media	(2, 15)
Smaller facility footprint	Micro-footprint suites, less capital investment	(15, 16)
Real-time quality control	Automated monitoring, fewer errors	(1, 17)
Raw material/catalyst savings	Up to 75% cost reduction in chemical processes	(18)

Enhanced Consistency and Quality of the Product: Process Analytical Technology (PAT), which lowers batch variability and increases efficiency while enabling real-time monitoring, control, and product quality assurance, is crucial to pharmaceutical continuous manufacturing.[1, 19]

Table 2

Principal Advantages and Uses of PAT in CM

Benefit/ Function	Example PAT Tools/Approaches	Impact on CM Process	References
Real-time monitoring & control	NIR, Raman, IR, UV/Vis spectroscopy, FBRM	Ensures steady-state operation, detects deviations, enables rapid adjustments	(20, 21)
Blend and content uniformity	In-line/at-line NIR, Raman probes	Monitors API concentration, blend uniformity, supports RTRT	(22, 23)
Process optimization & automation	Advanced process control, self-optimizing algorithms	Enables dynamic adjustment of parameters, improves yield and efficiency	(24-26)
Data integration & model-based control	Multivariate models, RTD, data fusion	Enhances process understanding, supports predictive control	(23, 27)
Regulatory compliance & quality by design	QbD, CPV, RTRT frameworks	Facilitates regulatory approval, continuous process verification	(28)

Common PAT Tools in CM

NIR, Raman, IR, and UV/Vis are common PAT tools in CM spectroscopy that are used extensively for non-destructive, real-time monitoring of important quality parameters such product purity, blend uniformity, and API concentration.[22, 28]

Focused Beam Reflectance Measurement (FBRM): In crystallization, focused beam reflectance measurement, or FBRM, is used to track the size and shape of particles.[21, 29]

Multivariate Data Analysis & Model-Based Control: Advanced process control and the interpretation of complicated data are made possible by multivariate data analysis and model-based control.[19, 27]

Implementation and Difficulties

In order to monitor and regulate crucial process parameters and quality features, PAT instruments are incorporated at many stages (blending, granulation, coating, and crystallization).

Data management, calibration/model maintenance, and modifying PAT for novel dose forms or intricate procedures are among the difficulties.[24]

Increased Agility and Flexibility: Because CM systems are designed to be more adaptable, producers can respond swiftly to changes in the market or in consumer demand without undergoing a significant retooling process.[30] This flexibility is particularly crucial for lower volume, high-potency drugs and in situations that call for rapid scale-up, as was shown during the COVID-19 pandemic for RNA-based treatments.[30]

Less Environmental Impact: By optimizing resource utilization and cutting waste output, CM promotes more ecologically friendly pharmaceutical production techniques.[31]

Continuous Manufacturing's Difficulties

High Initial Investment: Installing a CM system usually requires a significant upfront investment in specialized equipment, advanced automation, and infrastructure.[30] This could be a significant barrier for small and medium-sized enterprises (SMEs).[30, 32]

Copyright © 2025. IJBR Published by Indus Publishers
This work is licensed under a Creative Commons Attribution 4.0 International License.

System Complexity and Integration: CM systems are inherently complex, necessitating sophisticated control systems and the seamless integration of multiple unit operations. This necessitates specialized expertise in domains such as systems engineering and data analytics.[32-34]

Limited Flexibility for Diversified Items: Although CM is great for large quantities of standardized items, it might not be able to adapt to frequent product modifications or highly diversified product portfolios without undergoing significant re-design.[35, 36]

Regulatory Considerations

Despite regulatory authorities' increasing support for CM, manufacturers may still encounter challenges navigating the evolving regulatory landscape and demonstrating equivalency to traditional batch processes.[30, 37, 38]

The Legal Framework Pertaining to Continuous Manufacturing: As they become more aware of CM's potential, international regulatory bodies like the FDA, EMA, and ICH are actively developing guidelines to aid in its implementation.[37, 39] ICH Q13, in particular, provides a framework for the development, use, and regulatory submission of continuous production.[40]

Prioritizing Real-time Data and Data Integrity: Regulatory agencies are focusing more on the dependability of data collection, management, and analysis within CM systems to ensure product quality and enable real-time release.[41] One of the most significant changes to the regulatory landscape for CM is this.[42]

Risk-Based Approaches: A risk-based approach to validation and control procedures is a crucial part of regulatory requirements for CM. This allows manufacturers to focus their resources on critical process parameters and quality attributes.[43]

Global Harmonization Efforts: Organizations like ICH are pushing for the harmonization of standards to speed up the approval process for CM products across different regions in order to minimize duplication of effort for pharmaceutical producers.[44]

Regulators are adapting to the increasing use of digital submissions, paperless dossiers, and AI-assisted tools in manufacturing and quality control, all while ensuring appropriate oversight and data integrity for these technologies.[45, 46]

Regulatory Structures for Gene, Cell, and Tissue-Engineered Advanced Therapy Medicinal Products (ATMPs): Advanced Therapy Medicinal Products (ATMPs), including gene therapies, somatic cell therapies, and tissue-engineered products,[47] are subject to particular frameworks due to their complexity and transformative potential.[48] The European Medicines Agency categorizes and approves ATMPs in the EU in accordance with Regulation 1394/2007.[49] In the US, ATMPs are regulated as biological products, but China and Thailand have their own systems.[50, 51] Two objectives of the evolving regulatory landscape are patient safety and timely access to innovative treatments.[52-54]

Describe ATMPs and the Particular Difficulties They Face: Advanced Therapy Medicinal Products (ATMPs) pose challenges in clinical development,[55, 56] quality assurance, and manufacturing due to their biological complexity.[57, 58] Among the solutions for clinical development and regulatory compliance are decentralized manufacturing models, automation, and artificial intelligence.[59-61]

Manufacturing Complexity: ATMPs can have short shelf lives and often need highly specialized, patient-specific manufacturing processes.[62, 63] As a result, the supply chain must strictly adhere to Good Manufacturing Practices (GMP).[64, 65]

Variable Starting Materials : Due to their biological nature, ATMPs may require stringent quality control procedures and may have variable starting materials (like patient cells).[66, 67]

Purity, Potency, and Identification Testing: One of the biggest challenges is creating sensitive and dependable assays to evaluate the identification, potency, and purity of these complex items.[68, 69]

Safety and Long-Term Effectiveness Follow-up

Due to the potential for long-lasting effects or delayed adverse events, regulatory bodies often request thorough long-term follow-up studies for ATMP recipients.[70]

The cold chain requirements, short shelf life, and occasionally customized nature of ATMPs present major logistical challenges for administration and transportation.[71]

Evolving Regulatory Pathways (2024-2025 Outlook): The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) are establishing new regulatory pathways to address the unique complexity of Advanced Therapeutic Products (ATMPs) and foster innovation.[71, 72] The EU provides ATMP developers with better scientific guidance and support, harmonizes GMP standards, and emphasizes a risk-based approach for clinical development and follow-up. [50, 53]The FDA works with developers,[23, 73] publishes comprehensive guidelines, offers accelerated programs, runs a Centre for Biologics.[74] Evaluation and Research, and aims for global standardization. Furthermore, new ATMP technologies such as combination products and advanced gene-editing techniques are difficult for regulators to control, necessitating flexible and adaptive regulatory frameworks.[28, 75]

Pharmaceutical Development Using Process Analytical Technology (PAT) and Quality by Design (QbD)

Quality by Design and Process Analytical Technology are two key concepts in pharmaceutical development and manufacturing that promote a proactive, risk-based, and scientific approach for more dependable products and processes.[23, 76]

Quality by Design (QbD): An Active Method for Ensuring Quality: QbD is a systematic approach to drug development that places an emphasis on early design space creation,[76] product and process knowledge, and control over CPPs and CQAs.[77, 78]

Key principles and elements of QbD include[79]

Quality Target Product Profile (QTPP): From the perspective of the patient, the Quality Target Product Profile (QTPP) describes the desired quality attributes of the final product.[80-82]

Copyright © 2025. IJBR Published by Indus Publishers
This work is licensed under a Creative Commons Attribution 4.0 International License.

Critical Quality Attributes, or CQAs: The physical, chemical, biological, or microbiological characteristics or attributes that must be found to fall within a specific range, limit, or distribution to ensure the desired level of product quality.[81, 83, 84]

Risk Assessment: Systematically evaluating potential risks to the end product's quality and identifying critical raw material and process attributes.[85-87]

Design Space: Quality by Design (QbD), a science-based approach to pharmaceutical development, places a strong emphasis on understanding the product and manufacturing process from the beginning.[76, 88] It comprises establishing a design space and identifying and controlling important quality attributes and process parameters.[78] QbD uses ICH Q8-Q11 guidelines and risk management tools to reduce batch failures and streamline processes.[77] However, there are challenges, including the intricacy of data administration and technical issues.[77, 89] Recent trends include continuous production, AI-driven predictive modelling, and digital twins.[90]

Control Strategy: A collection of prearranged controls that guarantee process performance and product quality, generated from knowledge of the product and process.[91] This covers in-process controls, process parameters, and material attribute controls.[92, 93]

Lifecycle Management and Continuous Improvement: QbD is an ongoing process of learning, adapting, and improving throughout the lifecycle of a product.[94]

Process Analytical Technology (PAT): Enabling Real-time Control

To improve production processes, particularly in the pharmaceutical industry,[75] the FDA-defined Process Analytical Technology (PAT) framework incorporates advanced analytical techniques like spectroscopy,[95] imaging, and chemometric modelling. It aims for cost savings, shorter production cycles, and consistent product quality, all of which are in line with the principles of Quality by Design.[96] PAT is widely used in the manufacturing of solid and biopharmaceutical products, such as vaccines, active pharmaceutical ingredients, and monoclonal antibodies.[97] However, challenges remain in pollutant detection, data integration, and sensor development.[24, 74, 98, 99]

Spectroscopic Techniques: In a variety of unit activities (such as blending, granulation, and tableting), near-infrared (NIR), Raman, and UV-Vis spectroscopy are frequently employed for real-time monitoring of blend uniformity, content uniformity, moisture content, and particle size.[100, 101]

Chromatography: Continuous monitoring of impurity profiles and the concentration of active pharmaceutical ingredients (APIs) using online or at-line HPLC/UPLC.[102]

Particle Size Analyzers: In-line instruments for tracking the distribution of particle sizes during granulation, milling, or crystallization operations are called particle size analyzers.[103-105]

Chemometrics and Multivariate Data Analysis: Multivariate data analysis and chemometrics are crucial for gleaning valuable insights from the massive volumes of data produced by PAT instruments, facilitating process comprehension and control.[106-108]

Effects of PAT and QbD on Pharmaceutical Efficiency and Quality: The pharmaceutical business is significantly impacted by the synergistic application of QbD and PAT:

Improved Product Sturdiness and Quality: Quality by Design (QbD) and Process Analytical Technology (PAT),[76] which prioritize the identification of critical attributes and the implementation of real-time monitoring and control strategies, are revolutionizing pharmaceutical production.[109] By reducing batch failures and increasing product consistency, these methods improve process reliability.[110] However, successful implementation requires overcoming technical challenges and promoting interdisciplinary collaboration.[23, 111] As the market grows, the integration of AI, digital twins, and sophisticated data analytics provides more reliable products and patient-centered innovation.[112-114]

Enhanced Productivity and Shorter Development Time:

PAT makes real-time release testing (RTRT) possible, which lessens the need for drawn-out end-product testing and speeds up product delivery.[115] By offering a methodical framework for process optimization, QbD simplifies development.[116]

Cost Reduction: Significant cost savings in manufacturing are a result of improved process understanding, fewer rework or rejects, and optimum resource usage.[117, 118]

METHODOLOGY

Data collection: As part of the literature review's data collection process, peer-reviewed articles were methodically located and evaluated. The publications were found using the following keywords: Continuous Manufacturing and Digital Transformation, Pharmaceutical Manufacturing, Process Analytical Technology (PAT), Regulatory Landscape, and Pharmaceutical Quality.

Article Selection: We selected articles from the PubMed, Scopus, Web of Science, and Google Scholar databases. Depending on their applicability, systemic reviews, clinical trials, meta-analyses, and cohort studies were considered for Pharmaceutical Manufacturing and Continuous Manufacturing. Only English-language works published in indexed journals between 2015 and 2025 were included in the selection process, with an emphasis on subjects like digital transformation, biologics, pharmaceutical quality, gene therapy, cell therapy, tissue-engineered products, and quality by Design (QbD).

DISCUSSION

The pharmaceutical industry is evolving to increase the quality, efficiency, and accessibility of medicines with the aid of Continuous Manufacturing (CM), evolving ATMP regulations, and the integration of Quality by Design (QbD) with Process Analytical Technology (PAT). While CM offers benefits like productivity and real-time control, it also has disadvantages like complexity and high cost. ATMPs' biological complexity necessitates innovative solutions like decentralized manufacturing and adaptable regulatory frameworks. Because they provide real-time monitoring and systematic development to ensure the efficacy and quality of the finished product, PAT and QbD are crucial. The effective implementation of these

Copyright © 2025. IJBR Published by Indus Publishers
This work is licensed under a Creative Commons Attribution 4.0 International License.

advancements requires interdisciplinary collaboration, digital transformation, a skilled workforce, and harmonization of international regulations.

CONCLUSION

The pharmaceutical industry is undergoing a major transition driven by ongoing innovation and regulatory developments. Important motivators include the need for flexible production and regulatory strategies for Advanced Therapy Medicinal Products (ATMPs) as well as the effectiveness and quality of Continuous Production (CM). Process Analytical Technology (PAT) and Quality by Design (QbD) work together to enable these advancements by enabling faster development and more dependable products. To overcome challenges like high costs and complexity, interdisciplinary collaboration, workforce training, digital adoption (AI, digital twins), and international regulatory harmonization are required to provide safer, more effective, and more accessible medications.

Acknowledgment: Through this study we wish to show our gratitude to our organization, Hamdard University, Karachi. who has always motivated and supported in the whole journey of this research.

Declaration of Generative AI and AI-Assisted Technologies In The Writing Process

During the preparation of this work the author(s) used Chat GPT to enhance the readability of the article. After using this tool/service, the author(s) reviewed and edited the content as needed and took(s) full responsibility for the content of the publication.

REFERENCES

1. Kashinath KP, Sanjay LR, Ashokbhai MK, Roy S, Sardar MS, Kaity S. Continuous manufacturing based paradigm shift in pharmaceuticals production and current regulatory framework. Chemical Engineering Research and Design. 2025. https://doi.org/10.1016/j.cherd.2025.01.003
2. Kleinebudde P, Khinast J, Rantanen J. Continuous Manufacturing of Pharmaceuticals. 2017. https://doi.org/10.1002/9781119001348
3. Hyer A, Gregory D, Le Q, Kay K, Turnage J, Gupton B, et al. Continuous Manufacturing of Active Pharmaceutical Ingredients: Current Trends and Perspectives. Advanced Synthesis & Catalysis. 2023. https://doi.org/10.1002/adsc.202301137
4. Lee S, O'Connor T, Yang X, Cruz C, Chatterjee S, Madurawe R, et al. Modernizing Pharmaceutical Manufacturing: from Batch to Continuous Production. Journal of Pharmaceutical Innovation. 2015;10:191-9. https://doi.org/10.1007/s12247-015-9215-8
5. Vanhoorne V, Vervaet C. Recent progress in continuous manufacturing of oral solid dosage forms. International journal of pharmaceutics. 2020:119194. https://doi.org/10.1016/j.ijpharm.2020.119194
6. Vargas J, Nielsen S, Cárdenas V, Gonzalez A, Aymat E, Almodovar E, et al. Process analytical technology in continuous manufacturing of a commercial pharmaceutical product. International journal of pharmaceutics. 2018;538 1-2:167-78. https://doi.org/10.1016/j.ijpharm.2018.01.003
7. Roggo Y, Pauli V, Jelsch M, Pellegatti L, Elbaz F, Ensslin S, et al. Continuous manufacturing process monitoring of pharmaceutical solid dosage form: A case study. Journal of pharmaceutical and biomedical analysis. 2019:112971. https://doi.org/10.1016/j.jpba.2019.112971
8. Burcham C, Florence A, Johnson M. Continuous Manufacturing in Pharmaceutical Process Development and Manufacturing. Annual review of chemical and biomolecular engineering. 2018;9:253-81. https://doi.org/10.1146/annurev-chembioeng-060817-084355
9. Khanal O, Lenhoff A. Developments and opportunities in continuous biopharmaceutical manufacturing. mAbs. 2021;13.
10. Adamo A, Beingessner R, Behnam M, Chen J, Jamison T, Jensen K, et al. On-demand continuous-flow production of pharmaceuticals in a compact, reconfigurable system. Science. 2016;352:61-7. https://doi.org/10.1126/science.aaf1337
11. Hu C. Reactor design and selection for effective continuous manufacturing of pharmaceuticals. Journal of Flow Chemistry. 2021;11:243-63. https://doi.org/10.1007/s41981-021-00164-3
12. Janssen P, Fathollahi S, Dickhoff BHJ, Frijlink H. Critical review on the role of excipient properties in pharmaceutical powder-to-tablet continuous manufacturing. Expert Opinion on Drug Delivery. 2024;21:1069-79.
13. Nasr M, Krumme M, Matsuda Y, Trout B, Badman C, Mascia S, et al. Regulatory Perspectives on Continuous Pharmaceutical Manufacturing: Moving From Theory to Practice: September 26-27, 2016, International Symposium on the Continuous Manufacturing of Pharmaceuticals. Journal of pharmaceutical sciences. 2017;106 11:3199-206. https://doi.org/10.1016/j.xphs.2017.06.015
14. Wahlich J. Review: Continuous Manufacturing of Small Molecule Solid Oral Dosage Forms. Pharmaceutics. 2021;13.
15. Tang S-M, Pei W, Chuang M-H. PV chart management innovation based on production balance ratio: a case study of Company S's GaAs process improvement for compound semiconductors. The International Journal of Advanced Manufacturing Technology. 2025.
16. Maiser B, Kaiser K, Lobedann M, David L. Performance evaluation of an automated and continuous antibody purification process in a side-by-side comparability study. 2019.
17. Almaya A, De Belder L, Meyer R, Nagapudi K, Lin H, Leavesley I, et al. Control Strategies for Drug Product Continuous Direct Compression-State of Control, Product Collection Strategies, and Startup/Shutdown Operations for the Production of Clinical Trial Materials and Commercial Products. Journal of pharmaceutical sciences. 2017;106 4:930-43. https://doi.org/10.1016/j.xphs.2016.12.014
18. Suarez M, Tatarchuk B. Comparative economic analysis of batch vs. continuous manufacturing in catalytic heterogeneous processes: impact of catalyst activity maintenance and materials costs on total costs of manufacturing in the production of fine chemicals and pharmaceuticals. Journal of Flow Chemistry. 2025.
19. Rosas J, Brush P, Thompson B, Miller C, Overton P, Tugby N, et al. Implementation of a fully integrated CM direct compression and coating process at a commercial pharmaceutical facility - Part 2: PAT and RTD results for normal operational conditions batches. International journal of pharmaceutics. 2023:122814. https://doi.org/10.1016/j.ijpharm.2023.122814
20. Helgers H, Schmidt A, Lohmann L, Vetter F, Juckers A, Jensch C, et al. Towards Autonomous Operation by Advanced

Copyright © 2025. IJBR Published by Indus Publishers
This work is licensed under a Creative Commons Attribution 4.0 International License.

Process Control—Process Analytical Technology for Continuous Biologics Antibody Manufacturing. 2021;9:172. https://doi.org/10.3390/pr9010172
21. Zhao B, Zang H, Zhong L, Xiaobo, Wang H, Zhang H, et al. Review of the Application of PAT in the Pharmaceutical Continuous Crystallization Process. Current topics in medicinal chemistry. 2023.
22. Rish A, Henson S, Alam MA, Liu Y, Drennen J, Anderson C. Development of Calibration-Free/Minimal Calibration Wavelength Selection for Iterative Optimization Technology Algorithms toward Process Analytical Technology Application. International journal of pharmaceutics. 2022:121463.
23. Kim EJ, Kim JH, Kim MS, Jeong S, Choi D. Process Analytical Technology Tools for Monitoring Pharmaceutical Unit Operations: A Control Strategy for Continuous Process Verification. Pharmaceutics. 2021;13. https://doi.org/10.3390/pharmaceutics13060919
24. Liu P, Jin H, Chen Y, Wang D, Yan H, Wu M, et al. Process analytical technologies and self-optimization algorithms in automated pharmaceutical continuous manufacturing. Chinese Chemical Letters. 2023.
25. Hsieh H-W, Griffin D, Nambiar A, Sarkar N, Ismail HY, Saigal K, et al. PAT-Enabled Automated Feedforward Control: An Application to the Continuous Manufacture of Apremilast. Organic Process Research & Development. 2024. https://doi.org/10.1021/acs.oprd.4c00155
26. Sacher S, Poms J, Rehrl J, Khinast J. PAT implementation for advanced process control in solid dosage manufacturing - a practical guide. International journal of pharmaceutics. 2021:121408.
27. Asachi M, Camargo-Valero MA. Multi-sensors data fusion for monitoring of powdered and granule products: Current status and future perspectives. Advanced Powder Technology. 2023.
28. Neugebauer P, Zettl M, Moser D, Poms J, Kuchler L, Sacher S. Process analytical technology in Downstream-Processing of Drug Substances- A review. International journal of pharmaceutics. 2024:124412. https://doi.org/10.1016/j.ijpharm.2024.124412
29. Simon L, Simone E. CHAPTER 9. Process Analytical Technology in Continuous Crystallization. 2020:353-71.
30. Mirasol F. How Continuous Manufacturing is Advancing Bio/Pharma Production. 2025.
31. Kim EJ, Kim JH, Kim M-S, Jeong SH, Choi DH. Process analytical technology tools for monitoring pharmaceutical unit operations: a control strategy for continuous process verification. Pharmaceutics. 2021;13(6):919.
32. Hock SC, Siang TK, Wah CL. Continuous manufacturing versus batch manufacturing: benefits, opportunities and challenges for manufacturers and regulators. Generics and Biosimilars Initiative Journal. 2021;10(1):1-14.
33. Byrn S, Futran M, Thomas H, Jayjock E, Maron N, Meyer RF, et al. Achieving continuous manufacturing for final dosage formation: challenges and how to meet them. May 20–21, 2014 continuous manufacturing symposium. Journal of pharmaceutical sciences. 2015;104(3):792-802. https://doi.org/10.1002/jps.24247
34. Srai JS, Badman C, Krumme M, Futran M, Johnston C. Future supply chains enabled by continuous processing—Opportunities and challenges. May 20–21, 2014 Continuous Manufacturing Symposium. Journal of pharmaceutical sciences. 2015;104(3):840-9.
35. Kleinebudde P, Khinast J, Rantanen J. Continuous manufacturing of pharmaceuticals: John Wiley & Sons; 2017.
36. Burcham CL, Florence AJ, Johnson MD. Continuous manufacturing in pharmaceutical process development and manufacturing. Annual review of chemical and biomolecular engineering. 2018;9(1):253-81. https://doi.org/10.1146/annurev-chembioeng-060817-084355
37. Mookuparambil N. Continuous manufacturing in pharma: FDA perspective. FDLI Update. 2019:26.
38. Hyer A, Gregory D, Kay K, Le Q, Turnage J, Gupton F, et al. Continuous manufacturing of active pharmaceutical ingredients: current trends and perspectives. Advanced Synthesis & Catalysis. 2024;366(3):357-89.
39. Nasr MM, Krumme M, Matsuda Y, Trout BL, Badman C, Mascia S, et al. Regulatory perspectives on continuous pharmaceutical manufacturing: moving from theory to practice: September 26-27, 2016, international symposium on the continuous manufacturing of pharmaceuticals. Journal of pharmaceutical sciences. 2017;106(11):3199-206. https://doi.org/10.1016/j.xphs.2017.06.015
40. Ilin DV, Lazanyuk IV. Indian pharmaceutical market: a way towards leadership in generics. RUDN Journal of Economics. 2024;32(4):725-43.
41. Yoffe A, Liu J, Smith G, Chisholm O. Regulatory Reform Outcomes and Accelerated Regulatory Pathways for New Prescription Medicines in Australia. Therapeutic Innovation & Regulatory Science. 2022;57:271-86.
42. Gautam A, Pan X. The changing model of big pharma: impact of key trends. Drug discovery today. 2016;21 3:379-84.
43. Vila EDL, Buts C, Jegers M. A quantitative classification of OTC medicines regulations in 30 European countries: dispensing restrictions, distribution, pharmacy ownership, and pricing systems. Journal of Pharmaceutical Policy and Practice. 2023;16. https://doi.org/10.1186/s40545-023-00522-7
44. Lofgren H, Boer R. Pharmaceuticals in Australia: developments in regulation and governance. Social science & medicine. 2004;58 12:2397-407.
45. Suryawanshi S, Jain S, Sharma R, Chawla R, Arora S, Shukla V, et al. Current veterinary regulations and way ahead. Research in veterinary science. 2023;166:105101.
46. Hines P, González-Quevedo R, Lambert A, Janssens R, Freischem B, Edo JT, et al. Regulatory Science to 2025: An Analysis of Stakeholder Responses to the European Medicines Agency's Strategy. Frontiers in Medicine. 2020;7.
47. Iglesias-López C, Agustí A, Obach M, Vallano A. Regulatory Framework for Advanced Therapy Medicinal Products in Europe and United States. Frontiers in Pharmacology. 2019;10. https://doi.org/10.3389/fphar.2019.00921
48. Boonprasirt P, Nimvorapun S, Sawangjang C, Poonpolsub S, Yoongthong W, Dunkum P. Regulatory Frameworks for Advanced Therapy Medicinal Products in Thailand. Advances in experimental medicine and biology. 2023;1430:221-33.
49. López-Paniagua M, De La Mata A, Galindo S, Blázquez F, Calonge M, Nieto-Miguel T. Advanced Therapy Medicinal Products for the Eye: Definitions and Regulatory Framework. Pharmaceutics. 2021;13.
50. Detela G, Lodge A. EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation. Molecular Therapy Methods & Clinical Development. 2019;13:205-32.
51. Lu J, Xu L, Wei W-C, He W. Advanced therapy medicinal products in China: Regulation and development. MedComm. 2023;4.
52. Salmikangas P, Schuessler-Lenz M, Ruiz S, Celis P, Reischl I, Menezes-Ferreira M, et al. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective. Advances in experimental medicine and biology. 2015;871:103-30. https://doi.org/10.1007/978-3-319-18618-4_6

Copyright © 2025. IJBR Published by Indus Publishers
This work is licensed under a Creative Commons Attribution 4.0 International License.

53. Regulatory Aspects for Approval of Advanced Therapy Medicinal Products in the EU. Handbook of experimental pharmacology. 2023.
54. Mebarki M, Madelaine I, Larghero J, De Jorna R. Advanced therapy medicinal products: Regulatory framework, hospital and pharmaceutical circuits in Europe and France. Therapie. 2021. https://doi.org/10.1016/j.therap.2021.11.005
55. Haeusner S, Herbst L, Bittorf P, Schwarz T, Henze C, Mauermann M, et al. From Single Batch to Mass Production–Automated Platform Design Concept for a Phase II Clinical Trial Tissue Engineered Cartilage Product. Frontiers in Medicine. 2021;8.
56. Abou-El-Enein M. Regulatory Landscape and Emerging Trends in Advanced Therapy Manufacturing: An EU Perspective. Cell Therapy. 2021.
57. Bars C. Manufacturing of ATMP across development phases – the technology transfer journey. Cytotherapy. 2020;22.
58. Kropp M, Harmening N, Bascuas T, Johnen S, De Clerck E, Fernández V, et al. GMP-Grade Manufacturing and Quality Control of a Non-Virally Engineered Advanced Therapy Medicinal Product for Personalized Treatment of Age-Related Macular Degeneration. Biomedicines. 2022;10. https://doi.org/10.3390/biomedicines10112777
59. Zia S, Pizzuti V, Paris F, Alviano F, Bonsi L, Zattoni A, et al. Emerging technologies for quality control of cell-based, advanced therapy medicinal products. Journal of pharmaceutical and biomedical analysis. 2024;246:116182.
60. Aguilar-Gallardo C, Bonora-Centelles A. Integrating Artificial Intelligence for Academic Advanced Therapy Medicinal Products: Challenges and Opportunities. Applied Sciences. 2024.
61. Silva DN, Chrobok M, Ahlén G, Blomberg P, Sällberg M, Pasetto A. ATMP development and pre-GMP environment in academia: a safety net for early cell and gene therapy development and manufacturing. Immuno-Oncology and Technology. 2022;16.
62. Ham RT, Hoekman J, Hövels A, Broekmans A, Leufkens H, Klungel O. Challenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe. Molecular Therapy Methods & Clinical Development. 2018;11:121-30. https://doi.org/10.1016/j.omtm.2018.10.003
63. Abou-El-Enein M, Elsanhoury A, Reinke P. Overcoming Challenges Facing Advanced Therapies in the EU Market. Cell stem cell. 2016;19 3:293-7.
64. Pizevska M, Kaeda J, Fritsche E, Elazaly H, Reinke P, Amini L. Advanced Therapy Medicinal Products' Translation in Europe: A Developers' Perspective. Frontiers in Medicine. 2022;9.
65. Boráň T, Menezes-Ferreira M, Reischl I, Celis P, Ferry N, Gänsbacher B, et al. Clinical Development and Commercialization of Advanced Therapy Medicinal Products in the European Union: How Are the Product Pipeline and Regulatory Framework Evolving? Human gene therapy Clinical development. 2017;28 3:126-35. https://doi.org/10.1089/humc.2016.193
66. Salvatore V. Exploring Solutions to Foster ATMP Development and Access to Patients in Europe. European journal of health law. 2020;27 3:259-73.
67. Olesti E, Nuevo Y, Bachiller M, Guillen E, Bascuas J, Varea S, et al. Academic challenges on advanced therapy medicinal products' development: a regulatory perspective. Cytotherapy. 2024.
68. Rejón-Parrilla J, Espin J, Garner S, Kniazkov S, Epstein D. Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries. Frontiers in Pharmacology. 2023;14. https://doi.org/10.3389/fphar.2023.1199500
69. Cheramangalath U, Nasre R, Srikant Y. Graph Analytics Frameworks. 2020:99-122.
70. Isson J, Harriott J. Pillars of Business Analytics Success: The BASP Framework. 2012:15-33.
71. Schuessler-Lenz M, Herberts C, Reischl I, Ruiz S, Celis P, Beuneu C, et al. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products in Europe. Advances in experimental medicine and biology. 2023;1430:1-21.
72. Schneider C, Salmikangas P, Jilma B, Flamion B, Todorova L, Paphitou A, et al. Challenges with advanced therapy medicinal products and how to meet them. Nature Reviews Drug Discovery. 2010;9:195-201. https://doi.org/10.1038/nrd3052
73. Golemovic M. Advanced Therapy Medicinal Products – An Overview. 2018;1:21-5.
74. Glassey J, Gernaey K, Clemens C, Schulz T, Oliveira R, Striedner G, et al. Process analytical technology (PAT) for biopharmaceuticals. Biotechnology Journal. 2011;6.
75. Saravaiya S, Kojar M, Shaikh B, Upadhyay P. Process Analytical Technology (Pat) In Pharmaceutical Manufacturing: A Review. EPRA International Journal of Research & Development (IJRD). 2025.
76. Yang S, Hu X, Zhu J, Zheng B, Bi W, Wang X, et al. Aspects and Implementation of Pharmaceutical Quality by Design from Conceptual Frameworks to Industrial Applications. Pharmaceutics. 2025;17. https://doi.org/10.3390/pharmaceutics17050623
77. Lee S-H, Kim J-K, Jee J-P, Jang D-J, Park Y-J, Kim J-E. Quality by Design (QbD) application for the pharmaceutical development process. Journal of Pharmaceutical Investigation. 2022;52:649-82.
78. Simões A, Veiga F, Vitorino C. Question-based review for pharmaceutical development: An enhanced quality approach. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2023:114174. https://doi.org/10.1016/j.ejpb.2023.114174
79. Sangshetti J, Deshpande M, Zaheer Z, Shinde D, Arote R. Quality by design approach: Regulatory need. Arabian Journal of Chemistry. 2017;10.
80. Chaudhari G. Editorial introduction to first issue of GSC Biological and Pharmaceutical Sciences. 2017;1.
81. Wang S, Wang Y, Li Z, Hong Y, Wang Z, Fan J, et al. Early determination of potential critical quality attributes of therapeutic antibodies in developability studies through surface plasmon resonance-based relative binding activity assessment. mAbs. 2024;16. https://doi.org/10.1080/19420862.2024.2374607
82. Maurya R, Ramteke S, Jain NK. Quality by design (QbD) approach-based development of optimized nanocarrier to achieve quality target product profile (QTPP)-targeted lymphatic delivery. Nanotechnology. 2024;35.
83. He Y, Zhu M, Wang L, Wu J, Wang Q, Wang R, et al. Programmed Self-Elimination of the CRISPR/Cas9 Construct Greatly Accelerates the Isolation of Edited and Transgene-Free Rice Plants. Molecular plant. 2018;11 9:1210-3. https://doi.org/10.1016/j.molp.2018.05.005
84. Reusch D, Tejada M. Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology. 2015;25:1325-34.
85. Ahmed T, Kollipara S, Boddu R, Bhattiprolu A. Biopharmaceutics Risk Assessment—Connecting Critical Bioavailability Attributes with In Vitro,In Vivo Properties and Physiologically Based Biopharmaceutics Modeling to Enable Generic Regulatory Submissions. The AAPS Journal. 2023;25. https://doi.org/10.1208/s12248-023-00837-y
86. Glöser S, Espinoza L, Gandenberger C, Faulstich M. Raw Material Criticality in the Context of Classical Risk Assessment. Resources Policy. 2015;44:35-46.

Copyright © 2025. IJBR Published by Indus Publishers
This work is licensed under a Creative Commons Attribution 4.0 International License.

87. Borchert D, Zahel T, Thomassen Y, Herwig C, Suárez-Zuluaga D. Quantitative CPP Evaluation from Risk Assessment Using Integrated Process Modeling. Bioengineering. 2019;6.
88. Aru P, Gulhane M, Katekar V, Deshmukh S. Quality by Design (QbD) in pharmaceutical development: A comprehensive review. GSC Biological and Pharmaceutical Sciences. 2024.
89. Grangeia HB, Silva C, Simões SP, Reis M. Quality by Design in Pharmaceutical Manufacturing: a systematic review of current status, challenges and future perspectives. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2019. https://doi.org/10.1016/j.ejpb.2019.12.007
90. Mishra V, Thakur S, Patil A, Shukla A. Quality by design (QbD) approaches in current pharmaceutical set-up. Expert Opinion on Drug Delivery. 2018;15:737-58.
91. Chavez P-F, Stauffer F, Eeckman F, Bostijn N, Didion D, Schaefer C, et al. Control strategy definition for a drug product continuous wet granulation process: Industrial case study. International journal of pharmaceutics. 2022:121970.
92. Kim JY, Chun M, Choi D. Control Strategy for Process Development of High-Shear Wet Granulation and Roller Compaction to Prepare a Combination Drug Using Integrated Quality by Design. Pharmaceutics. 2021;13. https://doi.org/10.3390/pharmaceutics13010080
93. Schofield T, Robbins D, Miró-Quesada G. Critical Quality Attributes, Specifications, and Control Strategy. 2015:511-35.
94. Tamboli F, Mane P, Babaleshwar R, Mane D, Attar P, Disale P, et al. From concept to compliance: The role of QbD in modern product development. Current Trends in Pharmacy and Pharmaceutical Chemistry. 2025.
95. Gerzon G, Sheng Y, Kirkitadze M. Process Analytical Technologies - Advances in bioprocess integration and future perspectives. Journal of pharmaceutical and biomedical analysis. 2021;207:114379. https://doi.org/10.1016/j.jpba.2021.114379
96. Maruthamuthu M, Rudge S, Ardekani A, Ladisch M, Verma M. Process Analytical Technologies and Data Analytics for the Manufacture of Monoclonal Antibodies. Trends in Biotechnology. 2020;38:1169-86.
97. Zhong L, Gao L, Li L, Zang H. Trends-process analytical technology in solid oral dosage manufacturing. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2020.
98. Lundsberg-Nielsen L, Schlindwein W, Berghaus A. Process Analytical Technology (PAT). 2018:227-55.
99. Mali A, Jagtap M, Karekar P, Maruška A. A BRIEF REVIEW ON PROCESS ANALYTICAL TECHNOLOGY (PAT). International Journal of Current Pharmaceutical Research. 2016;8:10-5.
100. Khanolkar A, Patil B, Thorat V, Samanta G. Development of Inline Near-Infrared Spectroscopy Method for Real-Time Monitoring of Blend Uniformity of Direct Compression and Granulation-Based Products at Commercial Scales. AAPS PharmSciTech. 2022;23. https://doi.org/10.1208/s12249-022-02392-9
101. Khanolkar A, Thorat V, Patil B, Samanta G. Towards a real-time release of blends and tablets using NIR and Raman spectroscopy at commercial scales. Pharmaceutical Development and Technology. 2023;28:265-76.
102. Dhull P, Dunuweera S, Bietsch J, Bandu R, Wannere C, Achanta S, et al. Recent advances and application of liquid chromatography in pharmaceutical industry. Journal of Liquid Chromatography & Related Technologies. 2025;48:168-87.
103. Madarász L, Köte Á, Hambalkó B, Csorba K, Kovács V, Lengyel L, et al. In-line particle size measurement based on image analysis in a fully continuous granule manufacturing line for rapid process understanding and development. International journal of pharmaceutics. 2021:121280. https://doi.org/10.1016/j.ijpharm.2021.121280
104. Kumar V, Taylor M, Mehrotra A, Stagner W. Real-Time Particle Size Analysis Using Focused Beam Reflectance Measurement as a Process Analytical Technology Tool for a Continuous Granulation–Drying–Milling Process. AAPS PharmSciTech. 2013;14:523-30.
105. Madarász L, Mészáros LA, Köte Á, Farkas A, Nagy ZK. AI-based Analysis of In-line Process Endoscope images for Real-time Particle Size Measurement in a Continuous Pharmaceutical Milling Process. International journal of pharmaceutics. 2023:123060.
106. Ferreira A, Tobyn M. Multivariate analysis in the pharmaceutical industry: enabling process understanding and improvement in the PAT and QbD era. Pharmaceutical Development and Technology. 2015;20:513-27. https://doi.org/10.3109/10837450.2014.898656
107. Roussel S, Preys S, Chauchard F, Lallemand EJ. Multivariate Data Analysis (Chemometrics). 2014:7-59.
108. Paul A. Introduction to multivariate Data Analysis. 2017.
109. Chun M, Kim JY, Park E, Choi D. Development of a Robust Control Strategy for Fixed-Dose Combination Bilayer Tablets with Integrated Quality by Design, Statistical, and Process Analytical Technology Approach. Pharmaceutics. 2021;13.
110. Singh B. Product Development, Manufacturing, and Packaging of Solid Dosage Forms Under QbD and PAT Paradigm: DOE Case Studies for Industrial Applications. AAPS PharmSciTech. 2019;20. https://doi.org/10.1208/s12249-019-1515-8
111. Aksu B, De Beer T, Folestad S, Ketolainen J, Lindén H, Lopes J, et al. Strategic funding priorities in the pharmaceutical sciences allied to Quality by Design (QbD) and Process Analytical Technology (PAT). European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2012;47 2:402-5.
112. Zhang L, Mao S. Applications of quality by design (QbD) and its tools in drug delivery. Asian Journal of Pharmaceutical Sciences. 2016;11:144-5.
113. Sitre D, Kamble R. Articulation of Quality By Design Elements for Product Development and its Unique Applications. Journal of Drug Delivery and Therapeutics. 2020;10:253-61.
114. Amidon G, Polli J, Woodcock J, Yu L, Khan M, Hoag S, et al. Understanding Pharmaceutical Quality by Design. The AAPS Journal. 2014;16:771-83. https://doi.org/10.1208/s12248-014-9598-3
115. Drobnjakovic M, Hart R, Kulvatunyou B, Ivezic N, Srinivasan V. Current challenges and recent advances on the path towards continuous biomanufacturing. Biotechnology Progress. 2023;39.
116. Zobel-Roos S, Schmidt A, Mestmäcker F, Mouellef M, Huter M, Uhlenbrock L, et al. Accelerating Biologics Manufacturing by Modeling or: Is Approval under the QbD and PAT Approaches Demanded by Authorities Acceptable Without a Digital-Twin? Processes. 2019. https://doi.org/10.3390/pr7020094
117. Ko T-S, Lee J, Ryu D. Blockchain Technology and Manufacturing Industry: Real-Time Transparency and Cost Savings. Sustainability. 2018.
118. Yamashina H, Kubo T. Manufacturing cost deployment. International Journal of Production Research. 2002;40:4077-91. https://doi.org/10.1080/00207540210157178

Copyright © 2025. IJBR Published by Indus Publishers
This work is licensed under a Creative Commons Attribution 4.0 International License.